Background. Necrotizing fasciitis is a rapid progressive and potentially life-threatening infection. Although the relative emergence of non-synergistic single Gram-negative organisms as pathogen could be a therapeutic issue for clinicians, limited studies so far described the characteristics due to the low incidence.
Methods. We retrospectively reviewed clinical data of necrotizing fasciitis patients who were clinically diagnosed between May 2001 and December 2015 in university hospitals of three different cities of the Republic of Korea. We compared clinical characteristics and outcomes of patients with monomicrobial Gram-negative with those of the Gram-positive counterpart.
Results. A total of 115 patients with community acquired necrotizing fasciitis were identified. Among them, monomicrobial infections were 67 (58%) cases: 31 (27%) in the Gram-negative group and 36 (31%) in the Gram-positive group. The majority of Gram-negative group was E. coli followed by K. pneumonia and V. vulnificus. There were more cases of the Gram-negative group showing liver cirrhosis (39% vs. 14%, P = 0.02) and bacteremia (52% vs. 16%, P = 0.02). A total of 23 (10%) patients died within 30 days, including 15 (19%) in the Gram-negative group and 8 (10%) in the Gram-positive group (P = 0.02). In multivariable logistic regression, liver cirrhosis (adjusted odds ratio [aOR], 13.7; 95% confidence interval [CI], 2.9-67.0), treatment with antibiotics without surgery (aOR, 10.2; 95% CI, 2.1-48.3), and lower level of albumin (aOR 4.9; 95% CI, 1.6-14.9) were significantly associated with 30-day mortality.
Conclusion. Our findings suggest that necrotizing fasciitis caused by Gramnegative pathogen more often associated with liver cirrhosis and has poorer outcomes than the Gram-positive counterpart.
Disclosures. All authors: No reported disclosures. Background. Approximately 2 million Americans develop a diabetic foot ulcer (DFU) annually; >50% die and 5% lose a limb within 5 years. IDSA guidelines recommend multidisciplinary team care for these patients (moderate evidence). Little is known about who should compose the team or how the team should function (low evidence). We conducted a systematic review following PRISMA guidelines to evaluate the effect of multidisciplinary team care on major amputation in patients with DFU's and describe team composition and function.
Multidisciplinary Care Teams to Reduce Major Amputations for Patients
Methods. A medical reference librarian searched databases without date limits through May 26, 2017. Two independent reviewers screened abstracts and then full text using the following inclusion criteria: original article; reported the effect of multidisciplinary teams (≥2 specialties) on major amputation; included a control group; >50% of study patients had diabetes; in English. Abstracted data included study design, patient characteristics, team composition and function, and major amputation rates.
Results. We included 33 studies (Figure 1 ). Five (15%) were in the United States, and 27 (82%) were historically controlled trials. Thirty-two (97%) documented lower major amputation rates among patients cared for by a multidisciplinary team (Figure 2 ). Relative reductions ranged from 11 to 90%. A 12% relative increase was observed in the single study documenting increased rates of major amputation following multidisciplinary care. Thirty-six different specialties were represented in the 26 studies reporting team composition, including: endocrinology (85%), vascular surgery (73%), orthopedic surgery (65%), podiatry (54%), and infectious disease (50%). Teams functioned in the following settings: inpatient (30%), outpatient (15%), or both (55%). Among 12 studies reporting team function, the following topics were addressed: surgical debridement/offloading (66%), vascular disease (63%), infection (59%), and glycemic control (41%).
Conclusion. Care by multidisciplinary teams may help prevent major amputation for patients with DFUs. Team composition and function, and reductions in major amputation rates, varied considerably. Research directly comparing different models of multidisciplinary care is needed.
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